Home › Funds › Nepsis Inc. › HCAT
Nepsis Inc. position in HCAT
HEALTH CATALYST INC · Information Technology
Nepsis Inc. reported holding 2,989,705 shares of HCAT (HEALTH CATALYST INC) in its Q3 2026 13F filing — a position valued at US$5.2M, representing 1.63% of its reported portfolio and ranking #22 among its reported holdings. Nepsis Inc. has disclosed HCAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR
How Nepsis Inc.'s HCAT position evolved
Nepsis Inc. first disclosed a stake in HCAT in Q3 2023 at 905,804 shares (US$9.2M). The position peaked in Q3 2024 at 2,104,528 shares, worth US$17.1M. Across 13 filings, Nepsis Inc. increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 2,989,705 shares valued at US$5.2M. Notable position changes include a 68% increase in Q3 2024 (shares fell 13% over the following quarter), a 95% trim in Q4 2024 (shares fell 36% over the following quarter), a 2072% increase in Q1 2025 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 905.80K | $9.17M | New |
| Q4 2023 | 1.09M | $10.11M | Add |
| Q1 2024 | 1.16M | $8.72M | Add |
| Q2 2024 | 1.25M | $8.01M | Add |
| Q3 2024 | 2.10M | $17.13M | Add |
| Q4 2024 | 96.26K | $10.12M | Reduce |
| Q1 2025 | 2.09M | $9.47M | Add |
| Q2 2025 | 1.73M | $6.50M | Reduce |
| Q3 2025 | 1.51M | $4.31M | Reduce |
| Q4 2025 | 1.92M | $4.58M | Add |
| Q1 2026 | 1.88M | $2.38M | Reduce |
| Q2 2026 | 2.98M | $5.92M | Add |
| Q3 2026 | 2.99M | $5.17M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About HCAT and 13F data
HCAT (HEALTH CATALYST INC) is a Information Technology company. 7 other funds we track also report a position in HCAT — the largest reported positions include First Light Asset Management, LLC (US$25.5M), CDC Financial, Inc. (US$14.1M), Palogic Value Management, L.P. (US$9.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding HCAT
- First Light Asset Management, LLC 12.81M sh · $25.49M · Q2 2026
- CDC Financial, Inc. 7.09M sh · $14.11M · Q2 2026
- Palogic Value Management, L.P. 4.92M sh · $9.80M · Q2 2026
More on Nepsis Inc.
FAQ
How long has Nepsis Inc. held HCAT?
Nepsis Inc. has disclosed HCAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Nepsis Inc.'s current position in HCAT?
As of Q3 2026, Nepsis Inc. holds 2.99M shares of HCAT (HEALTH CATALYST INC), valued at $5.17M, representing 1.63% of its reported portfolio and ranking #22.
Has Nepsis Inc. been buying or selling HCAT?
In the latest 13F filing (Q3 2026), Nepsis Inc. held unchanged its position in HCAT. The position peaked in Q3 2024 at 2.10M shares.
Which other funds hold HCAT?
Other major institutional holders of HCAT include First Light Asset Management, LLC, CDC Financial, Inc., Palogic Value Management, L.P., among 7 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.